| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10806743 | BRAINTREE LABS | Method of administering lactitol to reduce plasma concentration of lactitol |
May, 2037
(13 years from now) | |
Pizensy is owned by Braintree Labs.
Pizensy contains Lactitol.
Pizensy has a total of 1 drug patent out of which 0 drug patents have expired.
Pizensy was authorised for market use on 12 February, 2020.
Pizensy is available in for solution;oral dosage forms.
Pizensy can be used as method of treating chronic idiopathic constipation in adult patients..
Drug patent challenges can be filed against Pizensy from 2024-02-13.
The generics of Pizensy are possible to be released after 12 May, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 12, 2025 |
Drugs and Companies using LACTITOL ingredient
NCE-1 date: 2024-02-13
Market Authorisation Date: 12 February, 2020
Treatment: Method of treating chronic idiopathic constipation in adult patients.
Dosage: FOR SOLUTION;ORAL
PIZENSY family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic